MRTX1133

Last updated
MRTX1133
MRTX1133.svg
Clinical data
Drug class Antineoplastic agents
ATC code
Identifiers
  • 4-(4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,7aS)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
PDB ligand
Chemical and physical data
Formula C33H31F3N6O2
Molar mass 600.646 g·mol−1
3D model (JSmol)
  • C#CC1=C(C=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OC[C@@]78CCCN7C[C@@H](C8)F)O)F
  • InChI=InChI=1S/C33H31F3N6O2/c1-2-23-26(35)7-4-18-10-22(43)11-24(27(18)23)29-28(36)30-25(13-37-29)31(41-15-20-5-6-21(16-41)38-20)40-32(39-30)44-17-33-8-3-9-42(33)14-19(34)12-33/h1,4,7,10-11,13,19-21,38,43H,3,5-6,8-9,12,14-17H2/t19-,20?,21?,33+/m1/s1
  • Key:SCLLZBIBSFTLIN-IFMUVJFISA-N

MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers. [1] [2] MRTX1133 was in a phase 1/2 clinical trial for the treatment of solid tumors, [3] however the study was terminated in Q1 2025. [4] MRTX1133 is considered to be harmful from direct skin or eye exposure other than transient irritation. It may cause irritation of the respiratory system if inhaled. [5]

See also

References

  1. ↑ "MRTX 1133". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD (November 2023). "Next batter up! Targeting cancers with KRAS-G12D mutations". Trends in Cancer. 9 (11): 955–967. doi: 10.1016/j.trecan.2023.07.010 . PMID   37591766.
  3. ↑ Clinical trial number NCT05737706 for "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation" at ClinicalTrials.gov
  4. ↑ "Bristol exits KRAS G12D". ApexOnco. Retrieved 22 June 2025.
  5. ↑ "MRTX1133 Safety Data Sheet". TargetMol. Retrieved 11 September 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.